Viking Thera (VKTX)

$29.41 -0.51 (-1.70%)
Market Cap 3.28B
Revenue (ttm) 0.00
Net Income (ttm) -109.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,785,900
Avg Vol 2,860,014
Day's Range N/A - N/A
Shares Out 113.04M
Stochastic %K 13%
Beta 0.71
Analysts Strong Sell
Price Target $93.06

Company Profile

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selectiv...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 704 4660
Address:
9920 Pacific Heights Boulevard, Suite 350, San Diego, United States
BeyondtheCouch
BeyondtheCouch Feb. 4 at 9:42 AM
$VKTX bears and shorts are digging up the cost of peptide again as their reason. Deliberately ignoring Viking saying 80/20 Subq v Oral and suggesting that Viking is all about a 100mg oral dose which is expensive. It’s a ludicrous short position to mantra, but I guess that shows how their story has run out
0 · Reply
UnchartedTrades
UnchartedTrades Feb. 4 at 9:24 AM
$VKTX biotech, NASH focus
0 · Reply
WernerZiegler
WernerZiegler Feb. 4 at 7:05 AM
$VKTX $NVO joint PR today?
0 · Reply
WernerZiegler
WernerZiegler Feb. 4 at 6:58 AM
$VKTX god candle is coming as all eyes on obesity
0 · Reply
WernerZiegler
WernerZiegler Feb. 4 at 6:57 AM
$VKTX and we have no PR of a confirmed ER/CC .. strange behavior. Novo possibly going to announce something else? 🤔
0 · Reply
FocusAdvancedCommunity
FocusAdvancedCommunity Feb. 4 at 6:50 AM
$VKTX $AMZN Biotech and large-cap
0 · Reply
DG20
DG20 Feb. 4 at 6:41 AM
$VKTX GLP/GIP >>>>> GLP/Amylin
0 · Reply
biolover
biolover Feb. 4 at 5:35 AM
$VKTX what is novo trying to do with this one day early release of numbers ? Absorb the shock ? Or declare different strategy next day ?
0 · Reply
DG20
DG20 Feb. 4 at 5:09 AM
$VKTX Novo’s problem is obvious and has been made repeatedly here for the last 2+ years. They are eroding market share because GLP/GIP is more effective at weightloss and more tolerable than ANY OTHER GLP COMBINATION (it’s also better @ A1C mgmt). Their next generation of Amylin co-agonists worsen side effects and still remain less effective than GLP/GIP @ weightloss. Worse for NVO is they are 2 years behind Viking and 1 year behind Roche plus there are other parties interested in entering obesity. They have the potential to be #3 in obesity by the end of the decade at this rate. NVO will be forced to come to come to the M&A table for Viking or someone else. The GLP industry unlike almost every other pharmaceutical pathway is led by patient preference and word of mouth. People are talking with their wallets. The CEO knew at JPM that there was going to be a revenue shortfall which is why they are willing to spend $20, 30 or even 40B to close the gap to LLY.
0 · Reply
JohnnyVacs
JohnnyVacs Feb. 4 at 4:22 AM
$VKTX HUGE VOLUME OVERNIGHT ALERT!!!! 134 shares 😂
0 · Reply
Latest News on VKTX
Obesity stocks slump on Novo's underwhelming 2026 sales forecast

Feb 3, 2026, 1:27 PM EST - 15 hours ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

ALT AMGN GPCR LLY NVO PFE

Viking Therapeutics, Inc. (VKTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 1:35 AM EST - 22 days ago

Viking Therapeutics, Inc. (VKTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Appetite for weight-loss deals broader than visible, Viking CEO says

Jan 12, 2026, 7:19 PM EST - 22 days ago

Appetite for weight-loss deals broader than visible, Viking CEO says

Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity

Jan 12, 2026, 7:00 AM EST - 22 days ago

Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity

Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity

Jan 8, 2026, 7:00 AM EST - 26 days ago

Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity

Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer

Jan 7, 2026, 7:00 AM EST - 27 days ago

Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer

Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 4:03 PM EST - 4 weeks ago

Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Novo Nordisk's weight-loss pill is available. Here's why Lilly's and Viking's stocks are down.

Jan 5, 2026, 10:57 AM EST - 4 weeks ago

Novo Nordisk's weight-loss pill is available. Here's why Lilly's and Viking's stocks are down.

LLY NVO

Viking Therapeutics: The Obesity Drugs Gold Rush Is Far From Over

Jan 3, 2026, 10:00 AM EST - 4 weeks ago

Viking Therapeutics: The Obesity Drugs Gold Rush Is Far From Over

Viking Therapeutics: A Wide-Open Oral GLP-1 Market

Jan 1, 2026, 2:13 AM EST - 4 weeks ago

Viking Therapeutics: A Wide-Open Oral GLP-1 Market

Viking Therapeutics' Swing Trade Potential Emerges - Competition/Dilution Risks Remain

Dec 28, 2025, 9:40 AM EST - 5 weeks ago

Viking Therapeutics' Swing Trade Potential Emerges - Competition/Dilution Risks Remain

Viking Therapeutics: Prepping For A Critical 2026

Dec 6, 2025, 8:57 AM EST - 2 months ago

Viking Therapeutics: Prepping For A Critical 2026

Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 4:05 PM EST - 2 months ago

Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference

3 Weight-Loss Drug Stocks To Consider For 2026

Nov 21, 2025, 1:58 PM EST - 2 months ago

3 Weight-Loss Drug Stocks To Consider For 2026

LLY NVO

Viking Therapeutics, Inc. (VKTX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 19, 2025, 4:48 AM EST - 2 months ago

Viking Therapeutics, Inc. (VKTX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735

Nov 19, 2025, 2:55 AM EST - 2 months ago

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735

Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025

Nov 6, 2025, 7:05 AM EST - 3 months ago

Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025

Druckenmiller's Viking Trade Just Hit A Golden Cross — And A Sweet 36% Gain

Nov 5, 2025, 10:01 AM EST - 3 months ago

Druckenmiller's Viking Trade Just Hit A Golden Cross — And A Sweet 36% Gain

Viking Therapeutics to Participate at Upcoming Investor Conferences

Nov 4, 2025, 4:05 PM EST - 3 months ago

Viking Therapeutics to Participate at Upcoming Investor Conferences

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025

Oct 29, 2025, 4:05 PM EDT - 3 months ago

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025

Viking Therapeutics Q3 Earnings: What We Learned (And Why We Should Keep Faith)

Oct 23, 2025, 10:42 AM EDT - 3 months ago

Viking Therapeutics Q3 Earnings: What We Learned (And Why We Should Keep Faith)

Viking Therapeutics: The Prime Target In The Obesity Gold Rush

Oct 23, 2025, 10:05 AM EDT - 3 months ago

Viking Therapeutics: The Prime Target In The Obesity Gold Rush

Viking Therapeutics, Inc. (VKTX) Q3 2025 Earnings Call Transcript

Oct 22, 2025, 7:33 PM EDT - 3 months ago

Viking Therapeutics, Inc. (VKTX) Q3 2025 Earnings Call Transcript

Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 22, 2025, 4:05 PM EDT - 3 months ago

Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity

Oct 21, 2025, 7:05 AM EDT - 3 months ago

Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity

Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025

Oct 15, 2025, 4:05 PM EDT - 3 months ago

Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025

Viking Therapeutics: A Speculative Buy

Oct 4, 2025, 9:44 AM EDT - 4 months ago

Viking Therapeutics: A Speculative Buy

Viking Therapeutics: Overdue For Gains

Sep 28, 2025, 2:00 PM EDT - 4 months ago

Viking Therapeutics: Overdue For Gains

Viking Therapeutics, Inc. (VKTX) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

Sep 23, 2025, 1:53 PM EDT - 4 months ago

Viking Therapeutics, Inc. (VKTX) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

Viking Therapeutics, Inc. (VKTX) Q4 2023 Earnings Call Transcript

Sep 22, 2025, 1:55 PM EDT - 4 months ago

Viking Therapeutics, Inc. (VKTX) Q4 2023 Earnings Call Transcript

Viking Therapeutics, Inc. (VKTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 8, 2025, 5:43 PM EDT - 5 months ago

Viking Therapeutics, Inc. (VKTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Viking: Still On Track, But The Compass Needs Recalibration

Aug 23, 2025, 6:57 AM EDT - 5 months ago

Viking: Still On Track, But The Compass Needs Recalibration

Viking Therapeutics: Panic Creates Opportunity

Aug 20, 2025, 8:52 PM EDT - 5 months ago

Viking Therapeutics: Panic Creates Opportunity

Viking Therapeutics: What's Happening With VKTX Stock?

Aug 20, 2025, 9:50 AM EDT - 5 months ago

Viking Therapeutics: What's Happening With VKTX Stock?

Why Viking Therapeutics stock reaction to obesity pill data is wildly ‘overdone'

Aug 19, 2025, 9:38 PM EDT - 6 months ago

Why Viking Therapeutics stock reaction to obesity pill data is wildly ‘overdone'

Mizuho's Jared Holz talks Viking Therapeutics' massive stock drop on obesity pill data

Aug 19, 2025, 6:27 PM EDT - 6 months ago

Mizuho's Jared Holz talks Viking Therapeutics' massive stock drop on obesity pill data

Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme'

Aug 19, 2025, 2:44 PM EDT - 6 months ago

Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme'

The market reaction is overdone on Viking Therapeutics, says BTIG's Justin Zelin

Aug 19, 2025, 1:45 PM EDT - 6 months ago

The market reaction is overdone on Viking Therapeutics, says BTIG's Justin Zelin

Viking Therapeutics plummets on new obesity drug data. Here's a breakdown

Aug 19, 2025, 12:19 PM EDT - 6 months ago

Viking Therapeutics plummets on new obesity drug data. Here's a breakdown

Viking Therapeutics Stock Plunges on Oral Weight-Loss Pill Study Results

Aug 19, 2025, 12:05 PM EDT - 6 months ago

Viking Therapeutics Stock Plunges on Oral Weight-Loss Pill Study Results

Viking Therapeutics: Wall Street Mistaken To Dump After Obesity Pill Study Success

Aug 19, 2025, 12:03 PM EDT - 6 months ago

Viking Therapeutics: Wall Street Mistaken To Dump After Obesity Pill Study Success

Viking Therapeutics Shares Nosedive Toward Worst Day Ever After Obesity Trial Data

Aug 19, 2025, 11:00 AM EDT - 6 months ago

Viking Therapeutics Shares Nosedive Toward Worst Day Ever After Obesity Trial Data

Viking Therapeutics shares fall more than 30% on disappointing obesity pill trial data

Aug 19, 2025, 9:39 AM EDT - 6 months ago

Viking Therapeutics shares fall more than 30% on disappointing obesity pill trial data

Like Eli Lilly, Viking Therapeutics' Oral Weight Loss Drug Disappoints, Stock Tanks

Aug 19, 2025, 9:28 AM EDT - 6 months ago

Like Eli Lilly, Viking Therapeutics' Oral Weight Loss Drug Disappoints, Stock Tanks

LLY

Viking Therapeutics' stock tumbles after results of oral weight-loss drug trial. It has company.

Aug 19, 2025, 9:11 AM EDT - 6 months ago

Viking Therapeutics' stock tumbles after results of oral weight-loss drug trial. It has company.

Viking Therapeutics stock tumbles 37% today, but here's why you should ‘HOLD'

Aug 19, 2025, 8:57 AM EDT - 6 months ago

Viking Therapeutics stock tumbles 37% today, but here's why you should ‘HOLD'

Viking Therapeutics' oral weight-loss pill meets expectations in mid-stage study

Aug 19, 2025, 7:18 AM EDT - 6 months ago

Viking Therapeutics' oral weight-loss pill meets expectations in mid-stage study

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

Aug 19, 2025, 7:08 AM EDT - 6 months ago

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

Viking Therapeutics: Still On Track

Aug 18, 2025, 8:56 PM EDT - 6 months ago

Viking Therapeutics: Still On Track

Viking Therapeutics Q2: Confidently Continuing The Recovery

Jul 25, 2025, 10:15 AM EDT - 6 months ago

Viking Therapeutics Q2: Confidently Continuing The Recovery

BeyondtheCouch
BeyondtheCouch Feb. 4 at 9:42 AM
$VKTX bears and shorts are digging up the cost of peptide again as their reason. Deliberately ignoring Viking saying 80/20 Subq v Oral and suggesting that Viking is all about a 100mg oral dose which is expensive. It’s a ludicrous short position to mantra, but I guess that shows how their story has run out
0 · Reply
UnchartedTrades
UnchartedTrades Feb. 4 at 9:24 AM
$VKTX biotech, NASH focus
0 · Reply
WernerZiegler
WernerZiegler Feb. 4 at 7:05 AM
$VKTX $NVO joint PR today?
0 · Reply
WernerZiegler
WernerZiegler Feb. 4 at 6:58 AM
$VKTX god candle is coming as all eyes on obesity
0 · Reply
WernerZiegler
WernerZiegler Feb. 4 at 6:57 AM
$VKTX and we have no PR of a confirmed ER/CC .. strange behavior. Novo possibly going to announce something else? 🤔
0 · Reply
FocusAdvancedCommunity
FocusAdvancedCommunity Feb. 4 at 6:50 AM
$VKTX $AMZN Biotech and large-cap
0 · Reply
DG20
DG20 Feb. 4 at 6:41 AM
$VKTX GLP/GIP >>>>> GLP/Amylin
0 · Reply
biolover
biolover Feb. 4 at 5:35 AM
$VKTX what is novo trying to do with this one day early release of numbers ? Absorb the shock ? Or declare different strategy next day ?
0 · Reply
DG20
DG20 Feb. 4 at 5:09 AM
$VKTX Novo’s problem is obvious and has been made repeatedly here for the last 2+ years. They are eroding market share because GLP/GIP is more effective at weightloss and more tolerable than ANY OTHER GLP COMBINATION (it’s also better @ A1C mgmt). Their next generation of Amylin co-agonists worsen side effects and still remain less effective than GLP/GIP @ weightloss. Worse for NVO is they are 2 years behind Viking and 1 year behind Roche plus there are other parties interested in entering obesity. They have the potential to be #3 in obesity by the end of the decade at this rate. NVO will be forced to come to come to the M&A table for Viking or someone else. The GLP industry unlike almost every other pharmaceutical pathway is led by patient preference and word of mouth. People are talking with their wallets. The CEO knew at JPM that there was going to be a revenue shortfall which is why they are willing to spend $20, 30 or even 40B to close the gap to LLY.
0 · Reply
JohnnyVacs
JohnnyVacs Feb. 4 at 4:22 AM
$VKTX HUGE VOLUME OVERNIGHT ALERT!!!! 134 shares 😂
0 · Reply
SlimyMango
SlimyMango Feb. 4 at 4:14 AM
$VKTX Just chillin’
0 · Reply
TrustButVerifi
TrustButVerifi Feb. 4 at 2:53 AM
$VKTX U wanna be a genius ? 4 Digit ticker on sale for 2 digit ! "but don't sleep on Viking Therapeutics (NASDAQ: VKTX). This $3.3 billion stock still has much to prove, but buying it now while it trades around $30 a share could make investors look like geniuses later."
0 · Reply
TrustButVerifi
TrustButVerifi Feb. 4 at 2:03 AM
$VKTX how many here think Viking is just gonna announce earning tomorrow out of the blue with no notice whatsoever?
2 · Reply
saifnila2
saifnila2 Feb. 4 at 1:55 AM
$VKTX initial cost of p3 trials was 300 million according to Zante. Now it appears they are tracking a whole lot more then that. They will be spending more then 100 million per quarter from here onwards. They initially said they are well financed for the sq program but now they need more. Needing a secondary end of this year or early next year.
0 · Reply
saifnila2
saifnila2 Feb. 4 at 1:49 AM
$VKTX this one will have a difficult time surviving without a partnership or buyout out. The idiot ceo is a total moron. Short on cash to the tune of half billion to program completion . Hats off to structure with 1.5 billion in cash and a safe path to program completion and marketing and possible solo survival.
0 · Reply
JohnnyVacs
JohnnyVacs Feb. 4 at 1:31 AM
$VKTX just go to 60
0 · Reply
SauceMan912
SauceMan912 Feb. 4 at 1:25 AM
$VKTX well, based off the immediate -3.5% sell off in overnight trading, I’m going to go ahead and guess that we will continue to be red tomorrow. Not sure if I have any hope left for this stock or company. 🤦🏼‍♂️
1 · Reply
TheStockShrewd
TheStockShrewd Feb. 4 at 1:20 AM
$NVO bid for $VKTX please 🙏🙏🙏🙏🙏🙏
0 · Reply
Stockman824
Stockman824 Feb. 4 at 1:12 AM
$VKTX who do we all THINK will Partner with Viking? Who do you WANT to Partner with Viking Think: ABBV Want:AMZN
2 · Reply
keylimepie2
keylimepie2 Feb. 4 at 1:10 AM
$VKTX Big lesson today: $NVO needs to move fast at the acquisition level. $PFE showed us today that $10 billion doesn’t buy best-in-class. They’ll need to dig much deeper to acquire $VKTX. But $NVO is in a tough position — maybe they wanted to wait for the Phase 3 readout, but after today, can they really take that risk? Other BP players know how vulnerable $NVO is, and it only makes sense that someone could jump in and buy $VKTX, which would seriously threaten $NVO’s market share.
2 · Reply
RunGal
RunGal Feb. 4 at 12:57 AM
$VKTX https://www.fool.com/investing/2026/02/03/the-smartest-growth-stock-to-buy-with-30-right-now/?.tsrc=rss
0 · Reply
Rickerthestockpicker
Rickerthestockpicker Feb. 4 at 12:55 AM
$VKTX Always Very Very
0 · Reply